Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
SYNLOGIC, INC. (SYBX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 8-K Quarterly results
Docs: "Synlogic Reports Second Quarter 2023 Financial Results and Provides Business Update - Recent milestones include initiation of the pivotal Phase 3 trial, Synpheny-3, and receipt of Fast Track designation for labafenogene marselecobac as a potential treatment for PKU - Cambridge, Mass. August 10, 2023 – Synlogic, Inc. , a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today reported financial results for the second quarter ended June 30, 2023, and provided an update on its pipeline programs. “With our pivotal Phase 3 study, Synpheny-3, now underway, we are focused on trial execution and ensuring access, inclusion and an optimal experience for the patients who participate in this landmark ..."
05/11/2023 8-K Quarterly results
Docs: "Synlogic Reports First Quarter 2023 Financial Results and Provides Business Update - Phenylketonuria program on track for Phase 3 trial initiation in first half of 2023 – - Recent milestones include receipt of Rare Pediatric and Orphan Drug Designations from the FDA, and orphan designation from the EMA for SYNB1934 as a potential treatment for PKU - Cambridge, Mass. May 11, 2023"
11/10/2022 8-K Quarterly results
08/11/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
03/17/2022 8-K Quarterly results
Docs: "Synlogic Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update",
"Presentation"
11/10/2021 8-K Quarterly results
Docs: "Synlogic Reports Third Quarter Financial Results and Provides Business Update",
"Presentation"
08/12/2021 8-K Quarterly results
03/25/2021 8-K Quarterly results
11/05/2020 8-K Quarterly results
Docs: "Synlogic Initiates Phase 1study of SYNB8802 for the Treatment of Enteric Hyperoxaluria",
"Synlogic Reports Third Quarter 2020 Financial Results and Provides Business Update",
"Presentation"
08/06/2020 8-K Quarterly results
05/08/2020 8-K Quarterly results
03/12/2020 8-K Quarterly results
11/12/2019 8-K Quarterly results
08/08/2019 8-K Quarterly results
Docs: "Synlogic Reports Second Quarter 2019 Financial Results and Provides Program Updates"
05/09/2019 8-K Quarterly results
Docs: "Synlogic Reports First Quarter 2019 Financial Results and Provides Business Update",
"402, CAMBRIDGE, MA 02142TEL: 617-401-9975WEB: WWW.SYNLOGICTX.COM"
03/12/2019 8-K Quarterly results
Docs: "Synlogic Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update"
11/13/2018 8-K Quarterly results
Docs: "Synlogic Reports Third Quarter 2018 Financial Results and Provides Program Updates"
08/08/2018 8-K Quarterly results
Docs: "Synlogic Reports Second Quarter 2018 Financial Results and Provides Program Updates"
03/20/2018 8-K Quarterly results
Docs: "Synlogic Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update"
11/13/2017 8-K Quarterly results
Docs: "Synlogic Reports Third Quarter 2017 Financial Results and Recent Progress"
05/09/2017 8-K Form 8-K - Current report
03/14/2017 8-K Form 8-K - Current report
11/10/2016 8-K Form 8-K - Current report
08/15/2016 8-K Quarterly results
Docs: "Mirna Therapeutics Reports Second Quarter 2016 Financial Results and Program Updates"
05/12/2016 8-K Form 8-K - Current report
03/29/2016 8-K Form 8-K - Current report
11/13/2015 8-K Quarterly results
Docs: "Mirna Therapeutics Reports Third Quarter Financial Results and Recent Highlights"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy